ERBB2 and breast carcinoma: Lapatinib, a tyrosine-kinase inhibitor that targets HER-2, together with capecitabine, provide a sound, concomitant treatment that has displayed clinical activity against brain metastases from HER-2 overexpressing breast cancer [23].